631 results
Page 19 of 32
8-K
EX-10.1
jz1u7u6gumd06htlc
31 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
vz44 8oz57ne8swr
25 Jul 12
Planned Acquisition of Amylin Expected to Add Two Marketed GLP-1 Agonists to Our Diabetes Franchise and Our Alliance with AstraZeneca
12:00am
8-K
EX-99.2
iam70xlt7wm964qbv9sk
25 Jul 12
Planned Acquisition of Amylin Expected to Add Two Marketed GLP-1 Agonists to Our Diabetes Franchise and Our Alliance with AstraZeneca
12:00am
8-K
EX-2.1
u8g7qrxst
3 Jul 12
Entry into a Material Definitive Agreement
12:00am
CORRESP
8ck24 2qk
17 May 12
Correspondence with SEC
12:00am
8-K
EX-99.1
nu18wqxd1d pv
26 Apr 12
Bristol-Myers Squibb Delivers a Solid First Quarter with Strong Operating Results and Key R&D Milestones
12:00am
DEFA14A
3mo93o
20 Mar 12
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
13a0 o9x4h
26 Jan 12
Net Sales Rise 7% to $5.5 Billion in Fourth Quarter
12:00am
SC TO-T
EX-99
n8r9u txw6fo
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
gv7q vz041y8
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
3mfxk
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
115ynoq59zoay kgjnyo
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
vqbo3f70gz87l67ac
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-10.1
vljf7p b4ge
4 Oct 11
Entry into a Material Definitive Agreement
12:00am